Prostate Cancer Radiogenomics—From Imaging to Molecular Characterization

International Journal of Molecular Sciences

卷:22

Mihai Dorin Vartolomei¹  Alessandro Sciarra²  Francesco Del Giudice²  Martina Maggi²  Felice Crocetto³  Biagio Barone³  Matteo Muto⁴  Daniela Terracciano⁵  Ugo Falagario⁶  Giuseppe Carrieri⁶  Luigi Cormio⁶  Gian Maria Busetto⁶  Matteo Ferro⁷  Gennaro Musi⁷  Ottavio de Cobelli⁷  Octavian Sabin Tataru⁸  Giuseppe Lucarelli⁹ 

[1] Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology from Târgu Mureș, 540142 Târgu Mureș, Romania;

[2] Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, “Sapienza” University of Rome, 00161 Rome, Italy;

[3] Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples “Federico II”, 80131 Naples, Italy;

[4] Department of Onco-Hematological Diseases, U.O.C. Radiotherapy–Azienda Ospedaliera San Giuseppe Moscati-(AV), 83100 Avellino, Italy;

[5] Department of Translational Medical Sciences, University of Naples “Federico II”, 80131 Naples, Italy;

[6] Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy;

[7] Department of Urology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy;

[8] The Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Sciences and Technology from Târgu Mureș, 540142 Târgu Mureș, Romania;

[9] Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy;

关键词: radiomics;    radiogenomics;    genomics;    prostate cancer;    molecular characterization;    MRI;   

DOI  :  10.3390/ijms22189971

来源: DOAJ

【 摘 要 】

Radiomics and genomics represent two of the most promising fields of cancer research, designed to improve the risk stratification and disease management of patients with prostate cancer (PCa). Radiomics involves a conversion of imaging derivate quantitative features using manual or automated algorithms, enhancing existing data through mathematical analysis. This could increase the clinical value in PCa management. To extract features from imaging methods such as magnetic resonance imaging (MRI), the empiric nature of the analysis using machine learning and artificial intelligence could help make the best clinical decisions. Genomics information can be explained or decoded by radiomics. The development of methodologies can create more-efficient predictive models and can better characterize the molecular features of PCa. Additionally, the identification of new imaging biomarkers can overcome the known heterogeneity of PCa, by non-invasive radiological assessment of the whole specific organ. In the future, the validation of recent findings, in large, randomized cohorts of PCa patients, can establish the role of radiogenomics. Briefly, we aimed to review the current literature of highly quantitative and qualitative results from well-designed studies for the diagnoses, treatment, and follow-up of prostate cancer, based on radiomics, genomics and radiogenomics research.

【 授权许可】

Unknown